A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO With the Standard Treatment EPREX in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis

Trial Profile

A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO With the Standard Treatment EPREX in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Recombinant erythropoietin (Primary) ; Epoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms BEAT_001
  • Sponsors Shenyang Sunshine Pharmaceutical
  • Most Recent Events

    • 12 Oct 2016 Planned End Date changed from 1 Feb 2017 to 1 Aug 2018.
    • 12 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.
    • 12 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top